Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related 		KEGG GENES KEGG DRUG DrugBank Disease ID
1 AGE-RAGE signaling pathway in diabetic complications 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
2 AGE-RAGE signaling pathway in diabetic complications 💬
 [2] VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
3 Bladder cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
4 Bladder cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
5 Calcium signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
6 Calcium signaling pathway 💬
 [2] VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
7 Chemical carcinogenesis - reactive oxygen species 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
8 Chemical carcinogenesis - reactive oxygen species 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
9 Chemical carcinogenesis - receptor activation 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
10 Chemical carcinogenesis - receptor activation 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
11 Collecting duct acid secretion 💬
 [2] ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299 💬
12 EGFR tyrosine kinase inhibitor resistance 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
13 EGFR tyrosine kinase inhibitor resistance 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
14 Fluid shear stress and atherosclerosis 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
15 Fluid shear stress and atherosclerosis 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
16 Focal adhesion 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
17 Focal adhesion 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
18 Gastric acid secretion 💬
 [2] ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299 💬
19 HIF-1 signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
20 HIF-1 signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
21 Human cytomegalovirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
22 Human cytomegalovirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
23 Human papillomavirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
24 Human papillomavirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
25 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
26 Kaposi sarcoma-associated herpesvirus infection 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
27 MAPK signaling pathway 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
28 MAPK signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
29 Metabolic pathways 💬
 [2] ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299 💬
30 MicroRNAs in cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
31 MicroRNAs in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
32 Oxidative phosphorylation 💬
 [2] ATP4A, ATP4B 💬 Lansoprazole 💬 Lansoprazole [7] 63, 71, 85, 98, 166, 222, 299 💬
33 Pancreatic cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
34 Pancreatic cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
35 Pathways in cancer 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
36 Pathways in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
37 PI3K-Akt signaling pathway 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
38 PI3K-Akt signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
39 Proteoglycans in cancer 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
40 Proteoglycans in cancer 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
41 Rap1 signaling pathway 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
42 Rap1 signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
43 Ras signaling pathway 💬
 [3] PGF, VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
44 Ras signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
45 Relaxin signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
46 Relaxin signaling pathway 💬
 [2] VEGFA, VEGFB 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
47 Renal cell carcinoma 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
48 Renal cell carcinoma 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
49 Rheumatoid arthritis 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
50 Rheumatoid arthritis 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬
51 VEGF signaling pathway 💬
 [1] VEGFA 💬 Aflibercept 💬 Aflibercept [2] 90, 166 💬
52 VEGF signaling pathway 💬
 [1] VEGFA 💬 Ranibizumab 💬 Ranibizumab [4] 34, 166, 227, 301 💬

Back to top